

RESPIRATORY SPECIALTY CARE PROGRAM

1 PATIENT INFORMATION:

Name: _____
 Address: _____
 City: _____ State: _____ Zip: _____
 Phone: _____ Alt. Phone: _____
 Email: _____
 DOB: _____ Gender: M F Caregiver: _____
 Height: _____ Weight: _____ Allergies: _____

2 PRESCRIBER INFORMATION:

Name: _____
 Address: _____
 City: _____ State: _____ Zip: _____
 Phone: _____ Fax: _____
 NPI: _____ DEA: _____
 Tax I.D.: _____
 Office Contact: _____ Phone: _____

3 STATEMENT OF MEDICAL NECESSITY: (Please Attach All Medical Documentation)

Date of Diagnosis: _____ ICD-10: _____ Secondary Diagnosis: _____ Date: _____

Diagnosis of moderate-to-severe asthma in patients ≥12 years old
 Diagnosis of moderate-to-severe eosinophilic asthma in patients ≥12 years old

Diagnosed by: Pulmonary Function Test Eosinophilic Level Assessment: Moderate Moderate to Severe Severe

Number of severe exacerbations in the past 12 months that required systemic corticosteroids, ER visits or hospitalizations: _____

Blood Eosinophil Level: _____ Test Date: _____
 IgE Level (if atopic comorbidities): _____ Test Date: _____

Pulmonary Function Test Results:
 Pre-bronchodilator FEV1: _____ Test Date: _____
 FeNO levels (if applicable): _____ Test Date: _____

Prior Failed Treatments:	Indicate Drug Name and Length of Treatment:
<input type="checkbox"/> Biologics _____	_____
<input type="checkbox"/> ICS _____	_____
<input type="checkbox"/> ICS + LABA _____	_____
<input type="checkbox"/> LABA _____	_____
<input type="checkbox"/> Nebulizer _____	_____
<input type="checkbox"/> Oral Corticosteroids _____	_____
<input type="checkbox"/> Other _____	_____

Diagnosis of chronic rhinosinusitis with nasal polyposis (CRSwNP) in patients ≥18 years old

Diagnosed by: Rhinoscopy Nasal endoscopy CT Scan
 Documentation of Ongoing Symptoms?
 Nasal Obstruction or Discharge Facial Pain or Pressure
 Reduction in or Loss of Smell N/A

Results and date of last CT scan or endoscopy, including polyp location/catheterization, if applicable: _____ Test Date: _____

History of Nasal Surgeries and Procedures? Yes No
 Endoscopic Polyp Removal (Polypectomy)
 Functional Endoscopic Sinus Surgery (FESS)
 Other: _____

If no, reason(s) patient may not be a candidate for surgery: _____

Prior Failed Treatments:	Indicate Drug Name and Length of Treatment:
<input type="checkbox"/> Oral Corticosteroids _____	_____
<input type="checkbox"/> Intranasal Corticosteroids _____	_____
<input type="checkbox"/> Medicated or Saline Nasal Rinse _____	_____
<input type="checkbox"/> Surgery _____	_____
<input type="checkbox"/> Other _____	_____

If Prior Authorization is denied, recommended formulary alternatives will be provided to the prescriber based upon the patient's insurance coverage.

4 INJECTION TRAINING: Pharmacist to Provide Training Patient Trained in MD Office Manufacturer Nurse Support

5 PRODUCT DELIVERY: Patient's Home Physician's Office Pharmacy to Coordinate

6 INSURANCE INFORMATION: Please Include Front and Back Copies of Pharmacy and Medical Card

PRESCRIPTION INFORMATION: (Please be sure to choose both induction and maintenance dose where applicable)

Patient Name: _____ Patient's Date of Birth: _____

Medication	Dosage & Strength	Direction	QTY	Refills
<input type="checkbox"/> DUPIXENT®	<input type="checkbox"/> 200mg/1.14ml Prefilled Syringe	For adults and adolescents 12 years of age and older:		
		<input type="checkbox"/> Induction Dose: Inject 400mg SC on day one	2	0
	<input type="checkbox"/> Maintenance: Inject 200mg SC every other week	2		
<input type="checkbox"/> 300mg/2ml Prefilled Syringe <input type="checkbox"/> 300mg/2ml Prefilled Pen	<input type="checkbox"/> Induction Dose: Inject 600mg SC on day one		2	0
	<input type="checkbox"/> Maintenance: Inject 300mg SC every other week		2	
		For adults with chronic rhinosinusitis with nasal polyposis:		
		<input type="checkbox"/> Inject 300mg SC every other week	2	
<i>For patients who require concomitant oral corticosteroids or with comorbid moderate to severe atopic dermatitis for which Dupixent® is indicated, start with an initial dose of 600mg SC followed by 300mg SC given every other week</i>				
<input type="checkbox"/>				

PRESCRIBER SIGNATURE: I authorize pharmacy to act as my designee for initiating and coordinating insurance prior authorizations, nursing services and patient assistance programs.

Signature: _____ Date: _____ Signature: _____ Date: _____

Substitution Permitted

Dispense As Written

Prior authorization approval and insurance benefits will be determined by the payor based upon the patient's eligibility, medical necessity, and the terms of the patient's coverage, among other things. Participation in this program is not a guarantee of prior authorization or of payment.

Confidentiality Notice: This fax is intended to be delivered only to the named addressee and contains confidential information that may be protected health information under federal and state laws. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please inform the sender immediately if you have received this document in error and then destroy this document immediately.